MarketBeat
27 Sept 2026, 00:03 UTC · 2h ago
Verdict
Headline takes no side. We score GMAB +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Genmab expects three pivotal Phase III oncology readouts in Q4 involving EPKINLY (DLBCL), Rina-S (ovarian cancer), and petosemtamab (head and neck cancer).
Priced instatements by VP of investor relations
So whatSuccess across these three results could trigger a triple-launch cycle in 2027, significantly shifting the company's revenue mix from royalties to standalone sales.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Petosemtamab colorectal cancer data will be presented at the ESMO congress from October 23 to October 27.
Priced inno timing evidence for announcement
So whatThis provides a concrete catalyst within the next 4 weeks to validate the 'encouraging signals' that accelerated the colorectal Phase III trials.
More positive than 87% of claims this week
Genmab projects petosemtamab could generate over $1 billion in sales by 2029.
Priced inreferenced as a projection
So whatAchieving this target would require capturing significant market share in head and neck and colorectal settings by FY2029.
More positive than 79% of claims this week
A Phase III readout for petosemtamab in second-line head and neck cancer based on overall survival is expected in Q1 2027.
Priced inno timing evidence for announcement
So whatThis provides a secondary valuation milestone shortly after the Q4 cluster, testing the asset's efficacy against J&J's Rybrevant.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company raised guidance following strong financial results and has three potential first-in-class Phase III readouts expected in Q4.
More negative than 61% of ticker scores this week
Mentioned as a competitor in the head and neck cancer space where Genmab believes its own asset compares favorably.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
12h ago
—
GMAB hasn't traded since this ran. Last close $35.32 (Sep 25); the reaction starts at the next open.
GMAB chart →
